摘要Graves眼病(Graves′ orbitopathy，GO)是Graves病(Graves′disease，GD)的主要甲状腺外表现。中度至重度GO是治疗的主要挑战，因其通常对现有的药物治疗反应不完全。糖皮质激素是中重度活动性GO的一线治疗方案，但有不少GO患者存在糖皮质激素治疗抵抗。研究已表明，白细胞介素(IL)-6受体参与了GO的发展。作为一种直接针对IL-6的重组人源化单克隆抗体，托珠单抗在临床研究中被证实对中到重度糖皮质激素抵抗的GO患者确有疗效，这表明靶向阻断IL-6受体的药物未来可能在GO治疗中占有一席之地。

abstractsGraves′orbitopathy (GO) is the main extrathyroidal manifestation of Graves′disease (GD). GO is a major therapeutic challenge in its moderate-to-severe forms, often incompletely responsive to available medical treatments. Glucocorticoids are the first-line treatment for moderate to severe active Graves′ orbitopathy (GO), but a certain amount of GO patients are still refractory to glucocorticoids treatment. Previous research have found that IL-6R participates in the development of GO. As a recombinant humanized monoclonal antibody directed against the IL-6 receptor, TCZ has shown its efficacy in moderate to severe glucocorticoid resistant GO patients. Therefore, drugs targeting IL-6R may claim its place in GO treatment someday.